Given this scenario, we tested whether a biomarker involved in the pathophysiological mechanisms that cause AMI, i.e. PKCe-expressing PLTs, may add diagnostic benefit to the conventional biomarker of myonecrosis, i.e. cardiac troponin. This evidence concerns the gene PRKCE and gas gangrene.